ARMO BioSciences Announces Pricing of Initial Public Offering
Summary
When available, copies of the final prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com ; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37 th Floor, Boston, MA 02110, by telephone at 800-808-7525 ext.ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors.The Company also has a number of other immuno-oncology product candidates aimed at treating a variety of cancers in combination with standard of care treatments and emerging immunotherapies.Related Links REDWOOD CITY, Calif., Jan. 25, 2018 /PRNewswire/ -- ARMO BioSciences, Inc. ("ARMO"), a late-stage immuno-oncology company, today announced the pricing of its initial public offering of 7,529,412 shares of its common stock at a price to the public of $17.00 per share for total gross proceeds of approximately $128.0 million.The shares are expected to begin trading on The Nasdaq Global Select Market on January 26, 2018 under the ticker symbol "ARMO."